DIABETES, Parkinson's disease, degenerative disc disease, macular degeneration, stroke — what do these have in common?

Plans for filing an IND was agreed with the FDA in a recent meeting –– Positive preclinical results of the small-diameter ATEV were recently ...

Pluripotent stem cells are cells that have the capacity to self-renew by dividing and to develop into the three primary germ cell layers of the early embryo and therefore into all cells of the ...

Due to these issues, the Company faced risks of the FDA failing to approve acellular tissue engineered vessel ("ATEV") for vascular trauma in a timely manner. Based on these facts, the Company's ...

On October 17, 2024, during market hours, the FDA released a Form 483 concerning Humacyte’s Durham, North Carolina facility, which revealed a number of violations, including “no microbial quality ...

Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

Development and Trends in Medical Aesthetic Material Technology Recent advancements in biocompatible materials have significantly improved the safety and effectiveness of medical aesthetic treatments ...

A new type of bioengineered blood vessel has shown strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...

Stem cells are cells that have the capacity to self-renew by dividing and to develop into more mature, specialised cells. Stem cells can be unipotent, multipotent, pluripotent or totipotent ...

Symvess is a sterile, acellular tissue-engineered vessel composed of extracellular matrix proteins usually found in human blood vessels and is manufactured using human vascular smooth muscle cells ...